influenza
respons
substanti
morbid
mortal
worldwid
global
influenza
estim
advers
affect
adult
children
year
annual
influenza
epidem
unit
state
result
nearli
lifeyear
lost
million
day
hospit
million
outpati
visit
addit
total
econom
burden
influenza
exce
billion
current
prevent
strategi
influenza
depend
use
antiinfluenza
medic
vaccin
neuraminidas
inhibitor
nai
eg
oseltamivir
approv
unit
state
prevent
treat
influenza
howev
use
antivir
medic
preexposur
prophylaxi
limit
role
gener
recommend
major
popul
also
nai
confer
modest
decreas
symptom
durat
individu
present
uncompl
ill
treatment
suffer
select
resist
strain
advers
effect
high
cost
effect
way
prevent
influenza
diseas
sever
outcom
vaccin
current
coverag
estim
well
healthi
peopl
goal
addit
vaccinestrain
mismatch
result
low
vaccin
efficaci
vaccin
may
also
contraind
unavail
less
effect
immunocompromis
individu
suffer
perceiv
risk
lead
vaccin
hesit
therefor
develop
effect
novel
strategi
prevent
treat
influenza
diseas
signific
unmet
need
cetylpyridinium
chlorid
cpc
use
decad
varieti
pathogen
disrupt
microbi
lipid
bilay
physicochem
interact
mechan
unlik
affect
mutat
addit
pathogen
independ
reason
cpc
quaternari
ammonium
compound
commonli
employ
prevent
bacteri
fungal
infect
within
healthcar
set
yet
littl
evid
demonstr
effect
respiratori
virus
evalu
cpc
efficaci
prototyp
respiratori
influenza
viru
demonstr
direct
virucid
activ
influenza
rapid
activ
follow
exposur
viral
ultrastructur
disrupt
absenc
influenza
resist
follow
prolong
exposur
prevent
treatment
influenza
infect
murin
model
viral
strain
influenza
strain
obtain
nation
influenza
repositori
influenza
oseltamivirresist
correspond
atcc
number
irr
irr
clinic
strain
influenza
viru
propag
patient
sampl
hereaft
refer
isol
oseltamivirresist
strain
contain
na
substitut
influenza
viru
strain
apuerto
obtain
atcc
propag
chicken
egg
cytotox
concentr
cpc
madin
darbi
canin
kidney
cell
mdck
atcc
number
cultur
confluenc
dmem
supplement
penicillinstreptomycin
lglutamin
fetal
calf
serum
gibco
ny
usa
increas
concentr
cpc
sigmaaldrich
st
loui
mo
dilut
phosphat
buffer
salin
pb
ad
media
incub
room
temperatur
minut
follow
exposur
cell
wash
time
dmem
remov
residu
cpc
complet
media
reappli
cell
return
viabil
quantit
neutral
red
uptak
hour
previous
describ
toxic
data
use
determin
cytotox
concentr
prism
softwar
influenza
cell
cultur
growth
influenza
viru
perform
previous
describ
briefli
mdck
grown
confluenc
follow
inocul
influenza
viru
multipl
infect
moi
hour
inoculum
remov
optimem
sigmaaldrich
st
loui
mo
appli
infect
cell
grown
hour
tissu
cultur
infect
dose
analysi
perform
detail
elsewher
defin
amount
viru
requir
produc
cytopath
effect
cultur
well
cytopath
effect
defin
focal
round
degen
chang
detach
cell
monolay
hemagglutin
assay
hemagglutin
assay
perform
describ
previous
briefli
viral
sampl
ad
cpc
dilut
pb
subsequ
incub
room
temperatur
minut
serial
dilut
mix
suspens
chicken
rbc
lampir
biolog
laboratori
pipersvil
pa
incub
room
temperatur
minut
data
present
percentag
reduct
ha
titer
rbc
expos
cpc
ensur
cpc
direct
lyse
effect
rbc
hemagglutin
titer
determin
end
point
dilut
pellet
observ
concentr
chicken
rbc
standard
use
hemocytomet
transmiss
electron
microscopi
tem
influenza
viru
chosen
prototyp
influenza
viru
treat
cpc
minut
cpc
concentr
employ
ensur
adequ
visual
cpc
activ
tem
analysi
still
remain
toxic
level
fifti
microlit
sampl
place
glass
slide
formvarcarbon
coat
tem
nickel
grid
mesh
place
sampl
face
minut
influenza
viru
treat
pb
use
sham
control
next
grid
remov
blot
filter
paper
expos
uranyl
acet
solut
addit
minut
excess
uranyl
acet
remov
grid
airdri
examin
fei
tecnai
spirit
electron
microscop
tei
hillsboro
oregon
imag
captur
use
gatan
ccd
camera
review
tem
analysi
mask
treatment
vs
control
slide
influenza
nucleoprotein
np
elisa
sampl
adsorb
overnight
costar
plate
well
wash
pb
tween
follow
block
bsa
g
bsa
ml
pb
next
well
expos
mous
antiinfluenza
b
np
antibodi
dilut
abcam
hour
follow
secondari
horseradish
peroxidaseconjug
goat
antimous
antibodi
dilut
abcam
hour
final
tetramethylbenzidin
tmb
elisa
substrat
abcam
minut
incub
perform
wash
perform
incub
reaction
termin
elisa
stop
solut
absorb
nm
quantifi
biorad
micropl
reader
od
valu
normal
unexpos
control
influenza
challeng
evalu
cpc
mice
wildtyp
mice
jackson
lab
bar
harbor
infect
intranas
x
pfumous
mouseadapt
influenza
strain
apuerto
atcc
viral
stock
propag
embryon
chicken
egg
titer
hemagglutin
assay
describ
viral
stock
titer
vivo
determin
clinic
formul
cpc
formul
glycerin
xanthan
gum
human
use
given
oral
determin
prophylact
efficaci
armsi
mice
treat
appli
oral
minut
challeng
twice
day
consecut
day
result
compar
oseltamivir
phosphat
mg
pb
appli
ip
twice
day
consecut
day
phosphat
buffer
salin
pb
alon
anim
observ
daili
gener
appear
bodi
weight
calcul
percentag
initi
weight
day
assess
therapeut
efficaci
armsi
mice
challeng
influenza
viru
treat
armsi
oral
either
hour
post
infect
hpi
time
day
day
dosag
chosen
match
recommend
label
usag
surviv
bodi
weight
measur
use
evalu
effect
describ
experi
approv
case
western
reserv
univers
institut
anim
care
use
committe
iacuc
protocol
statist
analysi
pairwis
comparison
perform
student
test
statist
signific
multipl
group
determin
oneway
analysi
varianc
anova
follow
tukeykram
multipl
comparison
test
kaplanmei
surviv
curv
compar
use
mantelcox
log
rank
test
follow
pairwis
comparison
use
wilcoxonbonferroni
correct
multipl
group
statist
analys
perform
prism
version
graph
pad
softwar
san
diego
ca
p
valu
consid
statist
signific
found
percentag
effect
concentr
cpc
influenza
virus
rang
tabl
hemagglutin
assay
well
cytotox
concentr
cpc
figur
demonstr
protect
vs
gener
cell
cytotox
confirm
microscop
visual
influenza
requir
higher
concentr
cpc
reduc
titer
wherea
influenza
b
significantli
suscept
disrupt
effect
cpc
p
base
data
determin
therapeut
index
cpc
rang
tabl
hemagglutin
assay
result
next
confirm
infecti
assay
specif
determin
concord
hemagglutin
data
observ
cpc
confer
log
reduct
influenza
viru
influenza
strain
test
influenza
b
appear
suscept
cpc
influenza
vs
respect
assess
suscept
cpc
differ
oseltamivirresist
influenza
strain
compar
virucid
activ
cpc
oseltamivirresist
viru
oseltamivirsuscept
strain
data
show
cpc
effect
suscept
resist
influenza
strain
tabl
show
resist
influenza
b
virus
suscept
isol
rang
notabl
valu
close
one
anoth
suggest
cpc
equal
effect
suscept
resist
viral
strain
likewis
cpc
confer
protect
suscept
resist
strain
measur
time
inactiv
figur
viru
infect
reduc
follow
minut
exposur
cpc
reduct
minut
taken
togeth
result
indic
cpc
substanti
rapid
within
minut
exposur
antivir
activ
suscept
resist
influenza
viru
mechan
action
cpc
influenza
viru
evalu
use
timecours
tem
analys
first
influenza
viru
expos
cpc
increas
period
exposur
remain
intact
viru
titer
ha
exposur
influenza
viru
cpc
minut
caus
decreas
viabil
viral
strain
test
except
attain
reduct
follow
exposur
moreov
continu
exposur
cpc
minut
led
decreas
influenza
titer
figur
second
tem
analys
show
viral
envelop
untreat
influenza
virus
intact
exposur
cpc
led
disrupt
envelop
gross
distort
viral
ultrastructur
eg
cavit
figur
presenc
neg
stain
interior
virion
treat
cpc
untreat
virion
suggest
permeabil
viral
membran
quantif
number
intact
disrupt
virus
treatment
reveal
virus
disrupt
lack
envelop
cpctreat
sampl
untreat
viru
prepar
pb
display
disrupt
nonenvelop
morpholog
confirm
cpc
disrupt
influenza
viru
envelop
use
elisa
monitor
releas
nucleoprotein
virus
respons
increas
concentr
cpc
found
exposur
viru
increas
concentr
cpc
result
significantli
increas
level
viral
nucleoprotein
media
supernat
p
figur
level
releas
nucleoprotein
reach
plateau
cpc
concentr
taken
togeth
result
demonstr
cpc
act
influenza
viru
rapid
disrupt
viral
envelop
evalu
potenti
cpc
induc
drug
resist
influenza
viru
expos
subinhibitori
concentr
cpc
follow
passag
drug
exposur
determin
figur
defin
cpc
resist
valu
mean
treatment
control
definit
stringent
use
influenza
medic
increas
note
concentr
either
influenza
b
demonstr
slight
increas
expos
cpc
passag
signific
note
influenza
b
suscept
cpc
continu
compar
influenza
result
suggest
cpc
low
potenti
select
influenza
viru
resist
consist
mechan
action
clinic
formul
cpc
name
use
prophylact
upper
respiratori
infect
random
doubleblind
clinic
trial
demonstr
topic
oral
cpc
formul
welltoler
reduc
sever
durat
cough
sore
throat
enrol
studi
particip
vs
control
group
although
clinic
efficaci
met
statist
signific
studi
power
address
efficaci
specif
pathogen
ie
influenza
determin
physiolog
relev
cpc
influenza
evalu
efficaci
cpcbase
clinic
formul
contain
cpc
wv
activ
ingredi
test
whether
confer
protect
wide
use
mouseadapt
influenza
strain
prophylact
therapeut
model
influenza
infect
evalu
prophylact
efficaci
armsi
show
bodi
weight
pbstreat
mice
significantli
reduc
day
post
infect
dpi
compar
armsi
treat
mice
p
figur
increas
rel
bodi
weight
armsitr
untreat
mice
rang
day
day
postinfect
note
armsitr
anim
tend
exhibit
higher
bodi
weight
oseltamivirtr
mice
signific
differ
note
day
vs
respect
p
increas
weight
armsitr
anim
consist
increas
activ
decreas
morbid
note
daili
observ
surviv
analysi
demonstr
armsitr
mice
exhibit
significantli
increas
surviv
compar
untreat
mice
p
figur
signific
differ
surviv
armsitr
vs
oseltamivirtr
group
given
promis
protect
observ
prophylact
next
ask
whether
armsi
might
protect
infecti
challeng
found
anim
treat
hpi
armsi
signific
weight
loss
contrast
anim
untreat
treat
hpi
exhibit
reduct
bodi
weight
first
day
figur
surviv
analysi
demonstr
armsi
treatment
hpi
significantli
increas
surviv
compar
untreat
mice
p
figur
mice
treat
hpi
armsi
also
increas
surviv
termin
experi
dpi
howev
differ
statist
signific
p
figur
vivo
studi
provid
physiolog
evid
cpcbase
treatment
may
efficaci
prevent
treatment
influenzaassoci
morbid
mortal
similarli
armsi
therapeut
protect
demonstr
given
hour
post
infect
c
bodi
weight
percentag
initi
weight
day
kaplanmei
surviv
curv
weight
report
mice
die
asterisk
indic
p
indic
either
vehicl
treatment
group
prophylact
b
therapeut
c
studi
respect
n
micegroup
one
similar
experi
shown
found
cpc
activ
suscept
oseltamivirresist
influenza
strain
cpc
disrupt
influenza
particl
rapidli
within
minut
exposur
analog
cpc
effect
pathogen
viral
resist
observ
prolong
exposur
multipl
passag
vitro
consist
physicochem
mechan
action
cpc
studi
demonstr
cpc
directli
disrupt
membran
subsequ
inhibit
infect
pathogen
influenza
virus
lastli
found
clinic
formul
cpc
reduc
influenzaassoci
morbid
mortal
vivo
find
signific
implic
prevent
influenza
cetylpyridinium
chlorid
one
activ
quaternari
ammonium
compound
qac
despit
use
food
pharmaceut
medic
industri
fifti
year
littl
data
specif
detail
mechan
action
virus
assum
cpc
direct
action
lipid
bilay
membran
particularli
cytoplasm
membran
lead
leakag
cytoplasm
content
lysi
microbi
cell
mechan
allow
broad
vari
spectrum
activ
among
differ
type
microorgan
bacteria
fungi
envelop
virus
hiv
describ
highli
suscept
studi
publish
date
effect
cpc
respiratori
viral
pathogen
influenza
demonstr
cpc
influenza
virus
within
clinic
meaning
rang
influenza
strain
cpcassoci
well
mdck
cell
consist
clinic
viabl
therapeut
index
interestingli
influenza
b
lower
compar
influenza
suggest
strain
suscept
effect
cpc
reason
remain
unclear
influenza
b
deriv
envelop
host
cell
howev
report
shown
phospholipid
composit
purifi
virion
differ
host
cell
wherea
phosphatidylcholin
major
compon
mammalian
cell
membran
purifi
virion
phosphatidylethanolamin
domin
addit
analysi
lipid
speci
viral
envelop
reveal
subtl
differ
influenza
b
strain
bilay
target
qac
differ
may
lead
alter
cpc
affin
result
chang
suscept
cpc
abil
cpc
perturb
viral
envelop
allow
broad
spectrum
activ
howev
histor
concern
toxic
cpc
may
result
underus
clinic
studi
therapeut
index
cpc
within
rang
consider
drug
develop
howev
import
note
mdck
cell
quit
robust
cytotox
test
cpc
humanderiv
cell
cell
may
add
understand
potenti
toxic
expect
longer
exposur
may
also
portend
increas
toxic
importantli
cpc
deem
safe
human
use
appli
concentr
addit
extens
safeti
studi
alreadi
conduct
cpc
includ
anim
pharmacokinet
absorpt
distribut
metabol
excret
adm
carcinogen
development
toxic
reproduct
toxic
studi
studi
conduct
wide
array
anim
model
mice
rat
hamster
rabbit
cat
dog
human
demonstr
cpc
safe
human
use
dose
use
studi
includ
wv
clinic
formul
lastli
random
doubleblind
clinic
trial
demonstr
cpc
formul
armsi
safe
well
toler
high
accept
protect
signal
virucid
kinet
cpc
influenza
virus
sensit
resist
oseltamivir
similar
rapid
antimicrobi
activ
describ
bacteria
fungi
similar
find
report
maillard
et
al
found
disrupt
bacteriophag
structur
occur
within
minut
follow
cpc
exposur
prevent
viral
invas
develop
diseas
cpc
broad
spectrum
rapid
virucid
activ
may
prefer
tem
nucleoprotein
releas
studi
show
cpc
disrupt
viral
envelop
although
experi
perform
use
influenza
b
prototyp
viru
expect
result
similar
influenza
observ
agreement
known
mechan
action
cpc
importantli
like
cpc
would
also
substanti
activ
envelop
virus
rsv
parainfluenza
coronaviru
common
annual
epidem
viral
pathogen
addit
influenza
highlight
unmet
need
broad
antivir
potenti
activ
cpc
nonenvelop
pathogen
includ
rhinoviru
bocaviru
adenoviru
remain
unclear
howev
sinc
cpc
shown
caus
structur
damag
nonenvelop
bacteriophag
agent
may
activ
nonenvelop
human
viral
pathogen
well
thu
evalu
cpc
effect
viral
pathogen
influenza
envelop
nonenvelop
potenti
clinic
valu
overus
nai
throughout
world
quickli
led
spread
neuraminidas
resist
contrast
qac
includ
cpc
activ
deploy
sinc
appar
reduct
effect
bacteria
fungi
reason
resist
cpc
observ
like
attribut
mechan
action
involv
bind
microbi
lipid
bilay
cpc
act
influenza
disrupt
lipid
envelop
analog
activ
bacteria
fungi
sinc
viral
envelop
host
deriv
physicochem
mechan
cpc
independ
intrins
viral
protein
unlik
influenc
mutat
shown
influenza
strain
signific
increas
passag
presenc
subinhibitori
cpc
concentr
lack
resist
potenti
cpc
contrast
dramat
develop
oseltamivir
resist
littl
passag
similar
condit
regard
subtherapeut
oseltamivir
exposur
result
increas
howev
continu
exposur
influenza
cpc
beyond
passag
perform
ensur
late
develop
resist
lastli
demonstr
protect
confer
cpcbase
clinic
formul
mous
model
influenza
often
drug
candid
possess
potent
vitro
inhibitori
activ
fail
test
vivo
found
mice
treat
either
follow
infecti
challeng
exhibit
significantli
increas
surviv
compar
vehicl
control
mice
compar
oseltamivirtr
mice
addit
toxic
detect
mice
treat
experiment
mous
model
fact
treatment
group
higher
weight
normal
activ
compar
untreat
pbstreat
oseltamivirtr
group
protect
promin
given
either
minut
hour
infect
time
point
prior
clinic
symptom
find
support
prophylact
use
indic
cpcbase
treatment
would
probabl
work
infect
establish
futur
studi
need
includ
similar
vivo
trial
ferret
anoth
import
anim
model
influenza
infect
assess
potenti
cpcbase
therapi
protect
influenza
diseas
conclus
demonstr
cpc
show
signific
activ
influenza
via
direct
virucid
activ
disrupt
viral
envelop
indic
resist
select
increas
surviv
observ
mice
treat
cpc
formul
compar
untreat
mice
find
similar
antiinfluenza
agent
oseltamivir
submit
cpc
abil
protect
influenza
respiratori
tract
infect
consid
clinic
develop
